For comments, suggestions
Created with Raphaël 2.1.0 21.12.2016 Filing date 06.07.2018 Validation fee payment 31.12.2018 (A1) Patent application published 16.03.2020 AGEPI application filing date 30.04.2020 (T2) Translation of the validated European patent 21.12.2022 Valid until 31.08.2023 (MM4E) Forfeiture of rights 31.07.2024 (MM4E) Forfeiture of rights

Patent lapsed


(210)Number of the EPO application16820005
(220)Filing date of the EPO application2016.12.21
(80)EPO patent specification publication (B)EPB nr. 10/2020, 2020.03.04
(110)EPO patent number3393478
(11)Number of the documentMD 3393478 T2
(21)Number of the applicatione 2018 1039
(71)Name(s) of applicant(s), code of the countryNuCana plc, GB;
(72)Name(s) of inventor(s), code of the countryGRIFFITH Hugh, GB;
(73)Name(s) of owner(s), code of the countryNUCANA plc, GB;
(54)Title of the inventionCombination therapy
(13)Kind-of-document code T2
(51)International Patent Classification A61K 31/7068 (2006.01.01); A61P 35/00 (2006.01.01); A61K 33/00 (2006.01.01)
(19)CountryGB
(41)Date of publication of the application2018.12.31
(49)Date of publication of the translation of the validated European patent specification2020.04.30
(30)PriorityPCT/GB2015/0541, 2015.12.23, WO; 201609770, 2016.06.03, GB
(74)Patent attorney(Procedură) FOCŞA Valentin, bd. Renaşterii Naţionale, No. 6, of. 08, MD-2024, mun. Chişinău, Republica Moldova
(86)International applicationPCT/GB2016/054018, 2016.12.21
(87)International publicationWO 2017/109486, 2017.06.29
Up
/Inventions/details/3393478